博士研究生导师简介
姓名
饶秋
研究方向：
分子病理诊断及泌尿系统肿瘤


联系方式
**；raoqiu1103@126.com

学术兼职：
《中华病理学杂志》杂志编委，《医学研究生学报》杂志编委，《东南国防医药》杂志编委。中华医学会病理学分会青年委员，中华病理学会泌尿学组组长，中华病理学会分子病理学组委员，中国病理医师协会委员，中国病理医师协会分子病理委员会委员，国家卫生和计划生育委员会病理质控评价中心（PQCC）分子病理组委员，中国实验医学病理专委会常委，中国老年医学学会病理分会委员，中国研究型医院学会分子诊断医学专委会常务委员兼青年委员会副主委，江苏省医学会病理学会委员，江苏省泌尿男生殖系肿瘤专业委员会委员，江苏省抗癌协会病理专业委员会委员，江苏省病理质控中心副主任，中国医促会病理分会委员，中国研究型医院病理分会委员，南京医学会病理专科分会副主任委员。

个人简介

博士，副主任医师，南京大学博导，南京医科大学硕士研究生导师,博士后合作导师。解放军东部战区总医院病理科主任。曾在美国印第安那大学病理系做访问****。江苏省333高层次人才；六大人才高峰。主持国家自然科学基金3项，江苏省自然科学基金1项。获得国家发明专利授权9项，新申报发明专利5项。近年来其相关研究获得了较多研究成果，发表论文100余篇，其中第一作者或通讯作者SCI论文40余篇，多篇于著名的Am J Surg Pathology、Modern Pathology、Histopathology等本学科国际著名杂志。多篇文章被2016版WHO泌尿及男生殖系统肿瘤分类引用。2012年获得刘志红院士青年医学奖。2013年荣获“吴秉铨病理学发展基金会”2013年度“优秀中青年****奖”。2015《中华病理学杂志》编委会表彰授予“金笔奖”。2016.10“中国****病理医师奖”。2017江苏省医学新技术引进奖一等奖（第一完成人）2018江苏省肿瘤医学二等奖（第一完成人）。

代表性论文[近5年通讯作者和第一作者]

1. Wang XT, Rao Q. Malignant melanotic Xp11 neoplasms exhibit a clinicopathologic spectrum and gene expression profiling akin to alveolar soft part sarcoma: a proposal for reclassification. J Pathol. 2020, 251(4):365-377. IF 5.979
2. Xia QY, Wang XT, Rao Q. Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum. Am J Surg Pathol. 2020;44(4):477-489. IF 5.878
3. Xia QY, Wang XT, Ye SB, Wang X, Li R, Shi SS, Fang R, Zhang RS, Ma HH, Lu ZF, Shen Q, Bao W, Zhou XJ,Rao Q. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH, Histopathology 2018,72(5):786-794. IF 3.2
4. Wang XT, Xia QY, Ye SB, Rao Q. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations, Mod Pathol. 2018,31(9):1346-1360. IF 6.655
5. Xia QY, Wang XT, Rao Q. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.Am J Surg Pathol. 2017,41(5):663-676. IF 5.878
6.Xia QY, Rao Q. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement. Mod Pathol. 2017,30(3):416-426. IF 6.655
7. Xia QY, Wang XT, Ye SB, Wang X, Li R, Shi SS, Fang R, Zhang RS, Ma HH, Lu ZF, Shen Q, Bao W, Zhou XJ, Rao Q. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH. Histopathology. 2018,72(5):786-794. IF 3.2
8. Wang XT, Xia QY, Ni H, Ye SB, Li R, Wang X, Shi SS, Zhou XJ, Rao Q. SFPQ/PSF-TFE3 Renal Cell Carcinoma (RCC): A Clinicopathologic Study Emphasizing Extended Morphology and Reviewing the Differences between SFPQ-TFE3 RCC and the Corresponding Mesenchymal Neoplasm despite an Identical Gene Fusion. Hum Pathol. 2017, 63:190-200. IF 3.2
9. Xia QY, Zhan XM, Fan XS, Ye SB, Shi SS, Li R, Wei X, Wang X, Ma HH, Lu ZF, Zhou XJ, Rao Q. BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation. Histopathology. 2017,70(5):711-721. IF 3.2
10. Qiu-yuan Xia, Xiao-tong Wang, Qiu Rao. Xp11 translocation renal cell carcinomas (RCCs) with RBM10-TFE3 gene fusion demonstrating melanotic features and overlapping morphology with t(6;11) RCC: interest and diagnostic pitfall in detecting a paracentric inversion of TFE3. American Journal of Surgical Pathology. 2017,41(5):663-676. IF 5.878
11. Ni H, Zhang XP, Wang XT, Xia QY, Lv JH, Wang X, Shi SS, Li R, Zhou XJ, Rao Q. Extended immunologic and genetic lineage of mammary analogue secretory carcinoma of salivary glands. Hum Pathol. 2016,58:97-104. IF 3.2
12. Rao Q, Xia QY, Cheng L, Zhou XJ. Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas. Chin J Cancer Res. 2016,28(1):29-49. Review. IF 3.2
13. Wang XT, Xia QY, Ni H, Wang ZY, Ye SB, Li R, Wang X, Lv JH, Shi SS, Ma HH, Lu ZF, Shen Q, Zhou XJ, Rao Q. Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum. Histopathology. 2016 Sep;69(3):450-8. IF 3.2
14. Rao Q, Shen Q, Xia QY, et al. PSF/SFPQ Is a Very Common Gene Fusion Partner in TFE3 Rearrangement-associated Perivascular Epithelioid Cell Tumors (PEComas) and Xp11 Translocation Renal Cancers: Clinicopathologic, Immunohistochemical, and Molecular Characteristics Suggesting Classification as a Distinct Entity. Am J Surg Pathol. 2015,39(9):1181-96. IF 5.878
15. Rao Q, Williamson SR, Zhang S, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013,37(6):804-15. IF 5.878
16. Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012,36(9):1327-38. IF 5.878
17. Rao Q, Williamson SR, Lopez-Beltran A, et al. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. Mod Pathol. 2013,26(5):725-32. IF 6.655
18. Rao Q, Xia QY, Wang ZY, et al. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Histopathology. 2015,67(1):121-9. IF 3.2
19. Rao Q, Cheng L, Xia QY, et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology. 2013,62(4):642-50. IF 3.2

承担科研项目[项目负责人]

2019-2022国家自然科学基金面上项目(** )
MiT基因家族相关融合基因转录调控mTORC1和自噬并驱动肾细胞癌代谢及增殖的机制研究
2015-2018 国家自然科学基金面上项目(** )
SWI/SNF染色质重塑复合物亚基BRM失活在肾透明细胞癌的致病机制研究
2012-2014 国家自然科学青年科学基金（**）
Xp11.2易位性肾癌及癌旁组织融合基因的分子病理研究
2011-2013 江苏省自然科学基金（BK**）
Xp11.2易位性肾癌的分子病理研究

获奖情况

2012年因工作成绩突出获得南京军区南京总医院刘志红青年医学奖。
2013年荣获“吴秉铨病理学发展基金会” 2013年度“优秀中青年****奖”。
2015.8因发表文章被引频率较高和数量较多被《中华病理学杂志》编委会表彰授予“金笔奖”。
2016.10“中国****病理医师奖”。
2017江苏省医学新技术引进奖一等奖（第一完成人）
2018江苏省肿瘤医学二等奖（第一完成人）